# Innoventric

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/innoventric

- Industry: Medical Devices & Equipment
- Headquarters: Rehovot, Israel
- Website: www.innoventric.com
- Total disclosed funding: $29M
- Latest round: Series B (Oct 29, 2024)
- Investors on record: 5

## About

Based in Ness Ziona, Israel, and founded in 2017 by CEO Amir Danino, CMO David Planer, and Business Development Head Rafi Benary, Innoventric Ltd., aka Innoventric, operates as a pharmaceutical company that provides transcatheter solutions for patients to improve life span and quality of life. In October 2024, Innoventric Ltd. raised USD 28.5 million in series B funding led by new investor RA Capital Management, with participation from returning investors BRM Group, JG Private Equity, and Mivtach Shamir Holdings Ltd. Another new investor EIC Fund also participated in the round. The trillium is an anatomical solution that helps in anchoring and bifurcation blood inflow, identifying accurate positioning in fluoroscopy-based procedures, allowing the required blood inflow, simplifying device positioning, and putting a tight seal while allowing hepatic vein inflow. As of 2024, the company had performed 10 implantations using trillium technology.

The company will use the funding to advance clinical trials and expand regulatory approvals in the US and Europe.

## Funding rounds

- Series B, Oct 29, 2024, $29M — BRM Group, RA Capital Management, European Innovation Council, Mivtach Shamir Holdings Ltd, JG Private Equity

## Investors

- BRM Group (https://capitalatlas.ai/funds/brm-group) — Series B
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series B
- European Innovation Council (https://capitalatlas.ai/funds/european-innovation-council) — Series B
- Mivtach Shamir Holdings Ltd — Series B
- JG Private Equity — Series B